Reducing Antibacterial Development Risk for GSK1322322 by Exploring Potential Human Dose Regimens in Nonclinical Efficacy Studies Using Immunocompetent Rats

Directly testing proposed clinical dosing regimens in nonclinical studies can reduce the risk during the development of novel antibacterial agents. Optimal dosing regimens can be identified in animal models by testing recreated human pharmacokinetic profiles. An example of this approach using contin...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Antimicrob Agents Chemother
Main Authors: Hoover, Jennifer L., Singley, Christine M., Elefante, Philippa, DeMarsh, Peter, Zalacain, Magdalena, Rittenhouse, Stephen
Formato: Artigo
Idioma:Inglês
Publicado em: American Society for Microbiology 2017
Assuntos:
Experimental Therapeutics
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5655044/
https://ncbi.nlm.nih.gov/pubmed/28807913
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.00959-17
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados